Using the Emerald Device to Find Digital Signs of Brain Energy Changes from Nicotinamide Riboside in Adults with Mild Cognitive Impairment or Mild Alzheimers Disease

What this Trial Is About

Researchers are investigating the use of passive sensing technology to identify digital markers related to brain energy changes from nicotinamide riboside supplementation in people with mild cognitive impairment or mild Alzheimers dementia. This observational study focuses on adults aged 18 to 89 who have either mild cognitive impairment or mild Alzheimers disease. The goal is to better understand bioenergetic metabolism, oxidative stress, and cognition through these digital markers. Participants will have the Emerald device, a radio-wave sensor, placed in their bedroom for up to 12 weeks. This device continuously monitors movement, breathing, gait, and sleep stages like Awake, Light, Deep, and REM without any physical contact or effort from the participant. The device uses low-powered radio signals and machine learning to convert reflections into detailed activity and sleep data, supplementing other biological and imaging information collected in the parent study. During the study, the Emerald device will collect continuous behavioral data while participants are also involved in the parent clinical trial. Researchers will assess outcomes such as sleep efficiency, gait speed over time, and daily activity rhythms across the 12-week period. This monitoring aims to provide digital biomarkers that relate to changes in brain bioenergetics and cognitive function. Participants usual care continues alongside this monitoring, and the study runs until May 2026.

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside